These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20677906)

  • 1. Manual aspiration prior to stenting does not reduce the incidence of filter no reflow in saphenous vein graft lesions protected by FilterWire EX/EZ.
    Jim MH; Yiu KH; Ko RL; Ho HH; Siu CW; Chow WH
    Acute Card Care; 2010 Sep; 12(3):92-5. PubMed ID: 20677906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Export aspiration catheter-enhanced FilterWire delivery: an innovative strategy for treatment of saphenous vein graft disease.
    Jim MH; Ho HH; Chow WH
    J Invasive Cardiol; 2006 Nov; 18(11):569-74. PubMed ID: 17090825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guiding-catheter thrombectomy combined with distal protection during primary percutaneous coronary intervention of a saphenous vein graft.
    García-Tejada J; Jurado-Román A; Hernández F; Asenjo RM; de Nicolás JM; Albarrán A; Velázquez M; Tascón J
    Cardiovasc Revasc Med; 2013; 14(6):356-8. PubMed ID: 24267597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.
    Stone GW; Rogers C; Hermiller J; Feldman R; Hall P; Haber R; Masud A; Cambier P; Caputo RP; Turco M; Kovach R; Brodie B; Herrmann HC; Kuntz RE; Popma JJ; Ramee S; Cox DA;
    Circulation; 2003 Aug; 108(5):548-53. PubMed ID: 12874191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial.
    Kereiakes DJ; Turco MA; Breall J; Farhat NZ; Feldman RL; McLaurin B; Popma JJ; Mauri L; Zimetbaum P; Massaro J; Cutlip DE;
    JACC Cardiovasc Interv; 2008 Jun; 1(3):248-57. PubMed ID: 19463308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of initial and residual thrombus burden on the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.
    Ahn SG; Choi HH; Lee JH; Lee JW; Youn YJ; Yoo SY; Cho BR; Lee SH; Yoon J
    Coron Artery Dis; 2015 May; 26(3):245-53. PubMed ID: 25503419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirating and filtering atherothrombotic debris during percutaneous coronary intervention.
    Bates ER
    JACC Cardiovasc Interv; 2008 Jun; 1(3):265-7. PubMed ID: 19463310
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravascular ultrasound findings that are predictive of no reflow after percutaneous coronary intervention for saphenous vein graft disease.
    Hong YJ; Jeong MH; Ahn Y; Kang JC; Mintz GS; Kim SW; Lee SY; Kim SY; Pichard AD; Satler LF; Waksman R; Weissman NJ
    Am J Cardiol; 2012 Jun; 109(11):1576-81. PubMed ID: 22440118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-graft abciximab and verapamil combined with direct stenting is a safe and effective strategy to prevent slow-flow and no-reflow phenomenon in saphenous vein graft lesions not associated with thrombus.
    Sharma S; Lardizabal JA; Singh S; Sandhu R; Bhambi BK
    Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):152-9. PubMed ID: 22559269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial.
    Badhey N; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Addo TA; Haagen D; Abdel-Karim AR; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger PB; Banerjee S; Brilakis ES
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):263-9. PubMed ID: 20665875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheolytic thrombectomy with distal filter embolic protection as adjunctive therapies to high-risk saphenous vein graft intervention.
    Ho PC; Leung CY
    Catheter Cardiovasc Interv; 2004 Feb; 61(2):202-5. PubMed ID: 14755812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Filter no-reflow during percutaneous coronary intervention of saphenous vein grafts: incidence, predictors and effect of the type of protection device.
    Porto I; Belloni F; Niccoli G; Larosa C; Leone AM; Burzotta F; Trani C; De Maria GL; Hamilton-Craig C; Crea F
    EuroIntervention; 2011 Dec; 7(8):955-61. PubMed ID: 22157481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up results after interventional treatment of infarct-related saphenous vein graft occlusion.
    Hoffmann R; Nitendo G; Deserno V; Adamu U; Almalla M; Blindt R; Vogt F
    Coron Artery Dis; 2010 Mar; 21(2):61-4. PubMed ID: 20124993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
    Jonas M; Stone GW; Mehran R; Hermiller J; Feldman R; Herrmann HC; Cox DA; Kuntz RE; Popma JJ; Rogers C;
    Eur Heart J; 2006 Apr; 27(8):920-8. PubMed ID: 16415300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Embolic protection devices in saphenous percutaneous intervention.
    Morís C; Lozano I; Martín M; Rondán J; Avanzas P
    EuroIntervention; 2009 May; 5 Suppl D():D45-50. PubMed ID: 19736070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention.
    Popma JJ; Cox N; Hauptmann KE; Reifart N; Virmani R; Emira K; Murphy S; Gibson CM; Grube E
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):125-34. PubMed ID: 12357506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative results of transluminal extraction coronary atherectomy in saphenous vein graft lesions with and without thrombus.
    Dooris M; Hoffmann M; Glazier S; Juran N; Reddy V; Grines CL; Pavlides GS; Schreiber T; O'Neill WW; Safian RD
    J Am Coll Cardiol; 1995 Jun; 25(7):1700-5. PubMed ID: 7759726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of saphenous vein graft stenting compared with native coronary artery stenting in patients with previous coronary artery bypass graft surgery.
    Eid-Lidt G; Gaspar J; Adames AE; Damas de Los Santos F; Valdez R I; Ramírez-Gutiérrez AE; Martínez-Ríos MA
    Arch Cardiol Mex; 2010; 80(1):3-9. PubMed ID: 21147555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts.
    Blackman DJ; Choudhury RP; Banning AP; Channon KM
    J Invasive Cardiol; 2005 Nov; 17(11):609-12. PubMed ID: 16264208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.